Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for Drug Resistant Epilepsy in a Real-World Setting: MORE Registry 2-year Results
Abstract number :
3.21
Submission category :
4. Clinical Epilepsy / 4C. Clinical Treatments
Year :
2021
Submission ID :
1826277
Source :
www.aesnet.org
Presentation date :
12/6/2021 12:00:00 PM
Published date :
Nov 22, 2021, 06:53 AM
Authors :
Jukka Peltola, MD, PhD. - University of Tampere and Tampere University Hospital; Albert Colon - Academisch Centrum voor Epileptologie (ACE) Kempenhaeghe/Maastricht UMC; José Pimentel - Department of Neurosurgery - Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Volker Coenen - Department of Stereotactic and Functional Neurosurgery - University Hospital Freiburg; Antonio Gil-Nagel - Neurology Department - Epilepsy Program - Hospital Ruber Internacional; António Gonçalves Ferreira - Department of Neurosurgery - Hospital Santa Maria, Centro Hospitalar de Lisboa Norte; Kai Lehtimäki - Department of neurology, neurosurgery and rehabilitation - University of Tampere and Tampere University Hospital; Philippe Ryvlin - Département des Neurosciences Cliniques - Centre Hospitalier Universitaire Vaudois (CHUV); Rod Taylor - MRC/CSO Social and Public Health Sciences Unit & Robertson Centre for Biostatistics - Institute of Health and Well Being University of Glasgow; Frans Gielen - Bakken Research Center; Thomas Brionne - Clinical Department - Medtronic International Trading; Abdallah Abouihia - Clinical Department - Medtronic International Trading; Paul Boon - Department of Neurology - Ghent University Hospital
Rationale: The efficacy of deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) in drug resistant epilepsy (DRE) patients was demonstrated in the double-blind Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE) randomized controlled trial. The Medtronic Registry for Epilepsy (MORE) aims to understand the safety and longer-term effectiveness of ANT-DBS therapy in routine clinical practice.
Methods: MORE is an observational registry collecting prospective and retrospective clinical data. Participants were at least 18 years old, with focal DRE recruited across 25 sites from 13 countries. They were followed for at least 2 years in terms of seizure frequency (SF), health-related quality of life (Quality of Life in Epilepsy Inventory 31,QOLIE-31), depression, and safety outcomes.
Results: Of the 191 patients recruited, 170 (mean (SD) age of 35.6 (10.7) years, 43% female) were analysed. At baseline, 38% of patients reported cognitive impairment. Over 2 years the median monthly SF decreased progressively by 33,1% (P < 0.0001) compared to baseline and QOLIE-31 improved by a median 2.3-point (P < 0.05). No change in depression severity was seen. In the subgroup of patients that completed 5 years of follow-up, SF was reduced by 55.1%. Factors influencing SF reduction included seizure type, absence of
Clinical Epilepsy